Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells

Heming Wei, Lu Fang, Jie Song, Subroto B Chatterjee

Research output: Contribution to journalArticle

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are known to inhibit leukocyte recruitment to endothelium but the mechanism is less understood. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is an endothelial junction protein involved in leukocyte diapedesis. We hypothesize that in endothelial cells, statins may well recruit PECAM-1 to exert their inhibitory effect on leukocyte trans-endothelial migration (TEM). In lovastatin-treated resting human umbilical vein endothelial cells (HUVECs), increased levels of mRNA and protein of PECAM-1 as well as its bio-synthesis (all ∼2-fold) were observed by real-time PCR, Western blotting and 35S-labeled methionine incorporation assay, respectively. Moreover, in lovastatin treated resting cells as well as TNF-α activated endothelial cells, unanimously decreased Triton X-100 insoluble and soluble PECAM-1 ratio was observed. Such changes were accompanied by decreased TEM of U-937 cells (a promonocyte cell line). All lovastatin's effects were abrogated by mevalonic acid. In resting HUVECs, geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP) (both are isoprenoid intermediates in the cholesterol biosynthesis pathway) compromised the effect of lovastatin on PECAM-1 expression, whereas C3 toxin, an inhibitor of small G proteins, exerted statin-like effect. Conclusion: Statin-reduced endothelial permeability could be attributed to altered intracellular distribution of PECAM-1 in endothelial cells. We speculate that lovastatin regulates PECAM-1 expression in HUVECs through the mevalonate-GGPP pathway by inhibiting of Rho small GTPase.

Original languageEnglish (US)
Pages (from-to)1272-1278
Number of pages7
JournalFEBS Letters
Volume579
Issue number5
DOIs
StatePublished - Feb 14 2005

Fingerprint

CD31 Antigens
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Endothelial cells
Lovastatin
Permeability
Endothelial Cells
Human Umbilical Vein Endothelial Cells
Mevalonic Acid
Leukocytes
Monomeric GTP-Binding Proteins
Biosynthesis
Monocyte-Macrophage Precursor Cells
Transendothelial and Transepithelial Migration
rho GTP-Binding Proteins
Terpenes
Octoxynol
Methionine
Endothelium
Real-Time Polymerase Chain Reaction
Assays

Keywords

  • Endothelial cell
  • eNOS
  • Lovastatin
  • PECAM-1
  • RhoA small GTPase
  • TNF-α

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. / Wei, Heming; Fang, Lu; Song, Jie; Chatterjee, Subroto B.

In: FEBS Letters, Vol. 579, No. 5, 14.02.2005, p. 1272-1278.

Research output: Contribution to journalArticle

@article{585a725aa4a9431f8d0f3adbab299c38,
title = "Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells",
abstract = "The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are known to inhibit leukocyte recruitment to endothelium but the mechanism is less understood. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is an endothelial junction protein involved in leukocyte diapedesis. We hypothesize that in endothelial cells, statins may well recruit PECAM-1 to exert their inhibitory effect on leukocyte trans-endothelial migration (TEM). In lovastatin-treated resting human umbilical vein endothelial cells (HUVECs), increased levels of mRNA and protein of PECAM-1 as well as its bio-synthesis (all ∼2-fold) were observed by real-time PCR, Western blotting and 35S-labeled methionine incorporation assay, respectively. Moreover, in lovastatin treated resting cells as well as TNF-α activated endothelial cells, unanimously decreased Triton X-100 insoluble and soluble PECAM-1 ratio was observed. Such changes were accompanied by decreased TEM of U-937 cells (a promonocyte cell line). All lovastatin's effects were abrogated by mevalonic acid. In resting HUVECs, geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP) (both are isoprenoid intermediates in the cholesterol biosynthesis pathway) compromised the effect of lovastatin on PECAM-1 expression, whereas C3 toxin, an inhibitor of small G proteins, exerted statin-like effect. Conclusion: Statin-reduced endothelial permeability could be attributed to altered intracellular distribution of PECAM-1 in endothelial cells. We speculate that lovastatin regulates PECAM-1 expression in HUVECs through the mevalonate-GGPP pathway by inhibiting of Rho small GTPase.",
keywords = "Endothelial cell, eNOS, Lovastatin, PECAM-1, RhoA small GTPase, TNF-α",
author = "Heming Wei and Lu Fang and Jie Song and Chatterjee, {Subroto B}",
year = "2005",
month = "2",
day = "14",
doi = "10.1016/j.febslet.2005.01.020",
language = "English (US)",
volume = "579",
pages = "1272--1278",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells

AU - Wei, Heming

AU - Fang, Lu

AU - Song, Jie

AU - Chatterjee, Subroto B

PY - 2005/2/14

Y1 - 2005/2/14

N2 - The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are known to inhibit leukocyte recruitment to endothelium but the mechanism is less understood. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is an endothelial junction protein involved in leukocyte diapedesis. We hypothesize that in endothelial cells, statins may well recruit PECAM-1 to exert their inhibitory effect on leukocyte trans-endothelial migration (TEM). In lovastatin-treated resting human umbilical vein endothelial cells (HUVECs), increased levels of mRNA and protein of PECAM-1 as well as its bio-synthesis (all ∼2-fold) were observed by real-time PCR, Western blotting and 35S-labeled methionine incorporation assay, respectively. Moreover, in lovastatin treated resting cells as well as TNF-α activated endothelial cells, unanimously decreased Triton X-100 insoluble and soluble PECAM-1 ratio was observed. Such changes were accompanied by decreased TEM of U-937 cells (a promonocyte cell line). All lovastatin's effects were abrogated by mevalonic acid. In resting HUVECs, geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP) (both are isoprenoid intermediates in the cholesterol biosynthesis pathway) compromised the effect of lovastatin on PECAM-1 expression, whereas C3 toxin, an inhibitor of small G proteins, exerted statin-like effect. Conclusion: Statin-reduced endothelial permeability could be attributed to altered intracellular distribution of PECAM-1 in endothelial cells. We speculate that lovastatin regulates PECAM-1 expression in HUVECs through the mevalonate-GGPP pathway by inhibiting of Rho small GTPase.

AB - The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are known to inhibit leukocyte recruitment to endothelium but the mechanism is less understood. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is an endothelial junction protein involved in leukocyte diapedesis. We hypothesize that in endothelial cells, statins may well recruit PECAM-1 to exert their inhibitory effect on leukocyte trans-endothelial migration (TEM). In lovastatin-treated resting human umbilical vein endothelial cells (HUVECs), increased levels of mRNA and protein of PECAM-1 as well as its bio-synthesis (all ∼2-fold) were observed by real-time PCR, Western blotting and 35S-labeled methionine incorporation assay, respectively. Moreover, in lovastatin treated resting cells as well as TNF-α activated endothelial cells, unanimously decreased Triton X-100 insoluble and soluble PECAM-1 ratio was observed. Such changes were accompanied by decreased TEM of U-937 cells (a promonocyte cell line). All lovastatin's effects were abrogated by mevalonic acid. In resting HUVECs, geranylgeranyl pyrophosphate (GGPP), but not farnesyl pyrophosphate (FPP) (both are isoprenoid intermediates in the cholesterol biosynthesis pathway) compromised the effect of lovastatin on PECAM-1 expression, whereas C3 toxin, an inhibitor of small G proteins, exerted statin-like effect. Conclusion: Statin-reduced endothelial permeability could be attributed to altered intracellular distribution of PECAM-1 in endothelial cells. We speculate that lovastatin regulates PECAM-1 expression in HUVECs through the mevalonate-GGPP pathway by inhibiting of Rho small GTPase.

KW - Endothelial cell

KW - eNOS

KW - Lovastatin

KW - PECAM-1

KW - RhoA small GTPase

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=13844276528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844276528&partnerID=8YFLogxK

U2 - 10.1016/j.febslet.2005.01.020

DO - 10.1016/j.febslet.2005.01.020

M3 - Article

VL - 579

SP - 1272

EP - 1278

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 5

ER -